#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare

Jul 27, 2026 Episode Page ↗
Overview

Peter Attia, MD, explores how obscure basic science discoveries have led to major medical breakthroughs. He traces the fascinating stories behind GFP, statins, ACE inhibitors, PCR, CRISPR, and GLP-1 agonists, making a case for investing in curiosity-driven research as essential for future medical innovation.

At a Glance
3 Insights
1h 4m Duration
11 Topics
8 Concepts

Deep Dive Analysis

Introduction: The Value of Basic Science in Medical Progress

The Discovery and Impact of Green Fluorescent Protein (GFP)

Nature's Toolkit: Evolution as a Source of Medical Solutions

The Discovery of Statins from Fungi

The Discovery of ACE Inhibitors from Snake Venom

The Discovery of PCR from Yellowstone Hot Springs Microbe

The Discovery of CRISPR from Salt Pond Archaea

The Discovery of GLP-1 Receptor Agonists from Gila Monster Venom

Recap: The Unpredictable Path of Medical Innovation

The Importance of Funding Curiosity-Driven Basic Research

Biomedical Science as a Continuum

Green Fluorescent Protein (GFP)

A protein isolated from jellyfish that emits green light when exposed to blue light. It's revolutionary because it folds itself, builds its own fluorescent core, and works in almost any cell or organism, allowing scientists to visualize biological processes in real-time.

HMG-CoA Reductase

A key enzyme in the body responsible for the rate-limiting step in cholesterol synthesis. Inhibiting this enzyme was understood to be a way to lower cholesterol levels, leading to the search for statins.

Bradykinin

A potent vasodilator peptide discovered from Brazilian pit viper venom. It is a fundamental player in mammalian cardiovascular biology, regulating blood pressure, vascular permeability, and inflammation.

Angiotensin Converting Enzyme (ACE)

An enzyme that converts angiotensin 1 to angiotensin 2 (a vasoconstrictor) and also degrades bradykinin (a vasodilator). Inhibiting ACE became a target for drugs to lower blood pressure.

Polymerase Chain Reaction (PCR)

A technique that allows scientists to make billions of copies of a specific DNA sequence in a test tube. It revolutionized molecular biology by enabling the amplification of DNA for genetic testing, forensic analysis, and gene therapy development.

Thermus aquaticus (Taq Polymerase)

A species of thermophilic bacteria discovered in Yellowstone hot springs that can thrive in extreme heat. Its DNA polymerase (Taq polymerase) is stable at high temperatures, making PCR practical by eliminating the need to add fresh enzyme in each cycle.

CRISPR

(Clustered Regularly Interspaced Short Palindromic Repeats) An adaptive immune system found in bacteria and archaea that stores snippets of viral DNA (spacers) to recognize and destroy future viral infections. This system was later engineered into a powerful gene-editing tool.

GLP-1 Receptor Agonists

A class of drugs that activate the glucagon-like peptide 1 (GLP-1) receptor, stimulating insulin secretion, suppressing appetite, and slowing gastric emptying. The first in this class, Exenatide, was derived from a peptide found in Gila monster venom.

?
How did basic, curiosity-driven research lead to major medical breakthroughs?

Many foundational medical advances, like GFP, statins, ACE inhibitors, PCR, CRISPR, and GLP-1 agonists, originated from scientists studying natural phenomena without an immediate clinical goal, driven purely by curiosity about how nature works.

?
What is the origin story of Green Fluorescent Protein (GFP)?

GFP was discovered by Osamu Shimamuru while studying how the Aequorea victoria jellyfish produces light, leading him to isolate two proteins, aquarin and GFP, the latter of which became a revolutionary tool for visualizing biology in living cells.

?
Where did statins, a class of cholesterol-lowering drugs, come from?

Statins originated from Akiro Endo's search for natural inhibitors of HMG-CoA reductase, leading him to discover a compound produced by Penicillium citronum fungus, which had evolved a chemical weapon to inhibit bacterial sterol synthesis.

?
How were ACE inhibitors, used for hypertension and heart failure, discovered?

ACE inhibitors trace back to the study of Brazilian pit viper venom, which causes a sudden drop in blood pressure, leading to the discovery of Bradykinin and later the identification of Angiotensin Converting Enzyme (ACE) and its inhibitors.

?
What is the surprising origin of PCR, a fundamental tool in molecular biology?

PCR was made practical by the discovery of Taq polymerase from Thermus aquaticus, a microbe found in Yellowstone hot springs by Thomas Brock, who was studying organisms that live in extreme temperatures.

?
How was CRISPR, the gene-editing tool, initially discovered?

CRISPR was discovered by Francisco Mojica, who was studying the genome of a salt-loving archaea and noticed strange repeating sequences that turned out to be a record of past viral infections, functioning as an adaptive immune system.

?
What is the unusual source of GLP-1 receptor agonists, used for diabetes and obesity?

GLP-1 receptor agonists were discovered by John Eng, who investigated why Gila monster venom caused pancreatic inflammation, leading him to isolate Exendin-4, a peptide similar to human GLP-1 but with a much longer half-life.

?
Why should society continue to invest in basic scientific research without immediate clinical goals?

Investing in curiosity-driven basic research is essential because we are 'demonstrably terrible' at predicting which projects will lead to transformative medical innovations, and many critical therapies have emerged from such seemingly irrelevant inquiries.

1. Prioritize Curiosity-Driven Research

Fund basic scientific research that explores fundamental questions about nature, even if its immediate clinical application is not obvious, as these often lay the groundwork for transformative medical breakthroughs.

2. Rethink Research Evaluation Criteria

Avoid solely judging research proposals based on their near-term translational impact or direct proximity to curing a disease, as this filter can overlook foundational discoveries.

3. Leverage Nature’s Solutions for Medicine

When seeking solutions to medical problems, recognize that evolution has already developed a vast toolkit of molecules and mechanisms; sometimes the most productive approach is to find the organism that already invented it.

He was a man with scissors, cutting rings off jellyfish, because he wanted to know how the animal glowed.

Peter Attia

Nature has been running experiments across millions of species for roughly 4 billion years... And while it hasn't solved our problems for us, it has often already created some of the components of the solutions we're looking for.

Peter Attia

If nature has already touched so many of these problems, then sometimes the most productive thing a scientist can do is not invent something new, it's to find the organism that already invented it.

Peter Attia

I want to study how a jellyfish glows is not a fundable proposal in that framework.

Peter Attia

We are demonstrably terrible at predicting which curiosity-driven work is going to matter.

Peter Attia
850,000
Jellyfish collected by Shimamuru Approximately 850,000 Aequorea victoria jellyfish bells were cut over 19 consecutive years (1961-1988).
30 years
Time GFP was ignored in literature Green Fluorescent Protein (GFP) was largely ignored in scientific literature for almost 30 years after its initial publication.
2008
Nobel Prize for GFP The Nobel Prize in Chemistry was awarded for the discovery and development of green fluorescent protein.
4 billion years
Years nature has run experiments Evolution has been running experiments across millions of species for roughly 4 billion years.
6,000+
Microbial strains screened for statins Akiro Endo and Masao Kuroda tested more than 6,000 microbial strains, mostly fungal, over two years to find an HMG-CoA reductase inhibitor.
1987
Lovastatin approval year Lovastatin, the first statin, was approved in the United States.
1981
Captopril approval year Captopril, the first oral ACE inhibitor, was approved by the FDA for clinical use.
55 degrees Celsius
Maximum temperature for bacterial growth (prevailing belief) The prevailing belief in microbiology was that bacteria could grow in conditions up to about 55 degrees Celsius.
88 degrees Celsius
Temperature of Octopus Spring Thomas Brock observed pink filamentous bacteria growing in water at 88 degrees Celsius in Yellowstone's Octopus Spring.
1969
Thermus aquaticus paper publication year Thomas Brock and Hudson Fries published a paper characterizing Thermus aquaticus, isolated from Yellowstone hot springs.
1 billion copies
PCR DNA amplification After 30 cycles of PCR, one DNA molecule can be turned into a billion copies.
1993
Nobel Prize for PCR Carey Mullis won the Nobel Prize in Chemistry for inventing Polymerase Chain Reaction.
30 base pairs
Length of CRISPR palindromic repeats CRISPR sequences consist of short, regularly spaced palindromic repeats of about 30 base pairs.
2005
Mojica's CRISPR paper publication year Francisco Mojica's paper identifying CRISPR as an adaptive immune system was finally published in the Journal of Molecular Evolution.
2020
Doudna and Charpentier Nobel Prize for CRISPR Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry for their work on CRISPR gene editing.
December 2023
Casgevy FDA approval year Casgevy, the first CRISPR-based therapy for sickle cell disease, received FDA approval.
53%
Amino acid sequence similarity of Exendin-4 to human GLP-1 Exendin-4, isolated from Gila monster venom, showed about 53% amino acid sequence similarity to human GLP-1.
2 minutes
Half-life of native human GLP-1 Native human GLP-1 has a half-life in the bloodstream of about two minutes.
2005
Exenatide (synthetic Exendin-4) FDA approval year Synthetic Exendin-4 (trade name Byetta, generic name Exenatide) was approved by the FDA for the treatment of type 2 diabetes.